Viropharma acquisition boosts Shire in 2014Shire’s acquisition of Viropharma last year helped its sales and earnings rocket in 2014, although chief executive Flemming Share XViropharma acquisition boosts Shire in 2014https://pharmaphorum.com/news/viropharma-acquisition-boosts-shire-in-2014/
Gilead cuts Sovaldi price in GermanyGilead has agreed a price cut with Germany’s main health insurers – to €41,000 ($46,625) for its hepatitis Share XGilead cuts Sovaldi price in Germanyhttps://pharmaphorum.com/news/gilead-cuts-sovaldi-price-in-germany/
Genzyme and Voyager collaborate on CNS gene therapiesGenzyme and Voyager Therapeutics are to collaborate on developing novel gene therapies for severe CNS disorders in an Share XGenzyme and Voyager collaborate on CNS gene therapieshttps://pharmaphorum.com/news/genzyme-and-voyager-collaborate-on-cns-gene-therapies/
ViiV tops reputation survey as Gilead tumblesAn annual review of the reputation of the top 37 pharma companies among patients reveals Gilead Sciences’ standing Share XViiV tops reputation survey as Gilead tumbleshttps://pharmaphorum.com/news/viiv-tops-reputation-survey-as-gilead-tumbles/
NHS ‘whistleblower’ report calls for change of cultureSir Robert Francis’ independent report on the Freedom to Speak Up review recommends ‘Guardians’ in every NHS Trust Share XNHS ‘whistleblower’ report calls for change of culturehttps://pharmaphorum.com/news/nhs-whistleblower-report-calls-for-change-of-culture/
GW Pharma moves beyond Sativex with epilepsy trialUK drugmaker GW Pharma will shortly start a Phase 3 trial programme for epilepsy drug Epidiolex, which some believe Share XGW Pharma moves beyond Sativex with epilepsy trialhttps://pharmaphorum.com/news/gw-pharma-moves-beyond-sativex-with-epilepsy-trial/
UK welcomes Gilead expansionGilead Sciences is the latest US pharma company expanding its presence in the UK, investing $19.6 million in Share XUK welcomes Gilead expansionhttps://pharmaphorum.com/news/uk-welcomes-gilead-expansion/
Medical group challenges Sovaldi’s EU patentA medical organisation is trying to overturn Gilead Sciences’ European patent for hepatitis C drug Sovaldi so cut-price Share XMedical group challenges Sovaldi’s EU patenthttps://pharmaphorum.com/news/medical-group-challenges-sovaldis-eu-patent/
Amgen’s John Kearney to be ABPI presidentThe Association of the British Pharmaceutical Industry (ABPI) has appointed John Kearney as president. He will take up Share XAmgen’s John Kearney to be ABPI presidenthttps://pharmaphorum.com/news/amgen-uk-chief-to-lead-abpi/
